Advertisement

PharmacoEconomics

, Volume 30, Issue 1, pp 47–61 | Cite as

Does the EQ-5D Reflect Lost Earnings?

  • Carl Tilling
  • Marieke Kro
  • Aki Tsuchiya
  • John Brazier
  • Job van Exel
  • Werner Brouwer
Original Research Article

Abstract

Background

An important methodological issue in economic evaluations of healthcare is how to include productivity costs (the costs related to reduced productivity due to illness, disability and premature death). Traditionally, they were included in the numerator of a cost-effectiveness analysis, through either the human-capital or the friction-cost method. It has been argued, however, that productivity costs are already included in the denominator (i.e. in the QALY measure) because respondents consider the effect a given health state will have on their income when valuing health states. If that is the case, many previous economic evaluations might have double counted productivity costs by including them in both the numerator and the denominator.

Aim

The aim of this study was to determine whether respondents valuing EQ-5D health states using the time trade-off (TTO) method spontaneously consider income effects, whether this consideration influences subsequent valuations and whether explicit ex post instructions influence valuations.

Methods

Through an online survey, we asked 321 members of the Dutch general population to value four EQ-5D health states through three different TTO exercises. The first exercise was a standard TTO question. Respondents were then asked whether they had included income effects. Depending on their answer, the second TTO exercise instructed them to either include or exclude income effects. The third TTO exercise provided explicit information regarding the income loss associated with the health state.

Results

Data were available from 321 members of the Dutch general public. Of these respondents, 49% stated they had spontaneously included income effects. Twenty-five percent of the sample did not trade any time in any of the TTO exercises and these respondents were excluded from the analysis. Results of t-tests showed there were only weakly significant differences in valuations for one health state between those who spontaneously included income effects and those who did not. Explicit instruction led to some significant differences at the aggregate level, but the effect was inconsistent at the individual level. When explicit information on the amount of income loss was provided, all states were valued lower when associated with a larger income loss.

Conclusions

This study offers further evidence indicating that income losses do not significantly affect health state valuations.

Keywords

Income Effect Explicit Instruction Income Loss High Valuation Random Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors would like to thank Lisa Gold, who discussed a version of this paper at the Health Economists’ Study Group meeting in Manchester in January 2009. They would also like to thank Allan Wailoo, who refereed a version of this paper for inclusion in the Health Economics and Decision Science discussion paper series. Finally, they would like to thank the respondents who took part in this study.

At the time the research was conducted, Carl Tilling was a PhD student funded by the Economic and Social Research Council. No other funding was used for the conduct of this study or preparation of this article.

References

  1. 1.
    National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (N1618). London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2008 Nov 1]
  2. 2.
    College voor Zorgverzekeringen. Dutch guidelines for pharmacoeconomic research [report ref. CURE/cuo.228/2]. Amstelveen: CVZ, 1999 [online]. Available from URL: www.ispor.org/PEguidelines/source/PE_guidelines_english_Netherlands.pdf [Accessed 2008 Nov 1]
  3. 3.
    Dolan P. Modelling valuations for EuroQol health states. Med Care 1997; 35 (11): 1095–108PubMedCrossRefGoogle Scholar
  4. 4.
    Lamers LM, McDonnell J, Stalmeier PFM, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuations studies. Health Econ 2006; 15 (10): 1121–32PubMedCrossRefGoogle Scholar
  5. 5.
    Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43 (3): 203–20PubMedCrossRefGoogle Scholar
  6. 6.
    Greiner W, Claes C, Buschbach JJV, et al. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2005; 6 (2): 124–30PubMedCrossRefGoogle Scholar
  7. 7.
    Brouwer WBF, Koopmanschap MA, Rutten FHH, et al. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6: 253–9PubMedCrossRefGoogle Scholar
  8. 8.
    Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996Google Scholar
  9. 9.
    Tilling CJ, Krol M, Tsuchiya A, et al. In or out? Income losses in health state valuations: a review. Value Health. 2010; 13 (2): 298–305PubMedCrossRefGoogle Scholar
  10. 10.
    Weisbrod BA. The valuation of human capital. J Polit Econ 1961; 69 (5): 425–36CrossRefGoogle Scholar
  11. 11.
    Rice D, Cooper B. The economic value of human life. Am J Public Health 1967; 57: 1954–66CrossRefGoogle Scholar
  12. 12.
    Koopmanschap MA, van Ineveld B. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005–10PubMedCrossRefGoogle Scholar
  13. 13.
    Krol M, Brouwer WBF, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter?. Pharmacoeconomics 2006; 24 (4): 401–14PubMedCrossRefGoogle Scholar
  14. 14.
    Davidson T, Levin LA. Do individuals consider expected income when valuing health states?. Int J Technol Assess Health Care 2008; 24 (4): 488–94PubMedCrossRefGoogle Scholar
  15. 15.
    Brouwer WBF, Grootenboer S, Sendi P. The incorporation of income and leisure in health state valuations when the measure is silent: an empirical inquiry into the sound of silence. Med Decis Making 2009; 29 (4): 503–12PubMedCrossRefGoogle Scholar
  16. 16.
    Krol M, Sendi P, Brouwer WBF. Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercises. Value Health 2009; 12 (10): 172–80PubMedCrossRefGoogle Scholar
  17. 17.
    Meltzer D, Weckerle CE, Chang LM. Do people consider financial effects in answering quality of life questions? [abstract]. Med Decis Making 1999; 19: 517CrossRefGoogle Scholar
  18. 18.
    Sendi P, Brouwer WBF. Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations. Health Econ 2005; 14: 643–7PubMedCrossRefGoogle Scholar
  19. 19.
    Myers J, McCabe S, Gohmann S. Quality-of-life assessment when there is a loss of income. Med Decis Making 2007; 27: 27–33PubMedCrossRefGoogle Scholar
  20. 20.
    Richardson J, Peacock S, Lezzi A. Do quality-adjusted life years take account of lost income? Evidence from an Australian survey. Eur J Health Econ 2009; 10 (1): 103–9PubMedCrossRefGoogle Scholar
  21. 21.
    Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002; 11 (4): 341–53PubMedCrossRefGoogle Scholar
  22. 22.
    Attema AE, Brouwer WBF. The correction for utility scores for utility curvature using a risk free utility elicitation method. J Health Econ 2009; 28 (1): 234–43PubMedCrossRefGoogle Scholar
  23. 23.
    Stata [computer program]. Version 9. College Station (TX): StataCorp, 2005Google Scholar
  24. 24.
    van Nooten FE, Koolman X, Brouwer WBF. The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ; 2009; 18 (5): 549–58PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Carl Tilling
    • 1
  • Marieke Kro
    • 1
    • 2
    • 3
  • Aki Tsuchiya
    • 1
    • 4
  • John Brazier
    • 1
  • Job van Exel
    • 2
    • 3
  • Werner Brouwer
    • 2
    • 3
  1. 1.School of Health and Related ResearchUniversity of SheffieldSheffieldUK
  2. 2.Institute for Medical Technology AssessmentErasmus University RotterdamRotterdamThe Netherlands
  3. 3.Institute of Health Policy and ManagementErasmus University RotterdamRotterdamThe Netherlands
  4. 4.Department of EconomicsUniversity of SheffieldSheffieldUK

Personalised recommendations